5月22日,丽珠医药宣布其间接全资附属公司拟以约17.28亿港元收购越南制药公司Imexpharm的64.81%股权。目标公司主要从事药品研发、生产和销售,产品涵盖抗生素和心脑血管药物。交割后,Imexpharm将成为丽珠医药间接非全资附属公司,并入账集团财务报表。此次收购助力丽珠医药拓展海外市场,推动国际化战略。当日早盘,丽珠医药股价上涨3.29%,报28.30港元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.